CL2023003491A1 - Derivados de triazina y su uso en el tratamiento del cáncer - Google Patents
Derivados de triazina y su uso en el tratamiento del cáncerInfo
- Publication number
- CL2023003491A1 CL2023003491A1 CL2023003491A CL2023003491A CL2023003491A1 CL 2023003491 A1 CL2023003491 A1 CL 2023003491A1 CL 2023003491 A CL2023003491 A CL 2023003491A CL 2023003491 A CL2023003491 A CL 2023003491A CL 2023003491 A1 CL2023003491 A1 CL 2023003491A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer treatment
- triazine derivatives
- compounds
- triazine
- derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000003918 triazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos novedosos que tienen la fórmula general Ib; en donde R1, R2, R3, R4, R5 y Z son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003491A1 true CL2023003491A1 (es) | 2024-05-24 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003491A CL2023003491A1 (es) | 2021-06-04 | 2023-11-23 | Derivados de triazina y su uso en el tratamiento del cáncer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240132471A1 (es) |
| EP (1) | EP4347571A1 (es) |
| JP (1) | JP2024522494A (es) |
| KR (1) | KR20240019083A (es) |
| AR (1) | AR126053A1 (es) |
| AU (1) | AU2022287224A1 (es) |
| BR (1) | BR112023025318A2 (es) |
| CA (1) | CA3216026A1 (es) |
| CL (1) | CL2023003491A1 (es) |
| CO (1) | CO2023016212A2 (es) |
| CR (1) | CR20230566A (es) |
| IL (1) | IL307201A (es) |
| MX (1) | MX2023013998A (es) |
| PE (1) | PE20240928A1 (es) |
| TW (1) | TW202313577A (es) |
| WO (1) | WO2022253936A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023131277A1 (zh) * | 2022-01-07 | 2023-07-13 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2024017924A1 (en) * | 2022-07-21 | 2024-01-25 | F. Hoffmann-La Roche Ag | Nlrp3 inhibitors |
| WO2024094185A1 (zh) * | 2022-11-04 | 2024-05-10 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| WO2024121086A1 (en) * | 2022-12-07 | 2024-06-13 | F. Hoffmann-La Roche Ag | Novel compounds as modulators of nlrp3 inhibition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022519636A (ja) * | 2019-02-04 | 2022-03-24 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CR20220356A (es) | 2020-01-22 | 2022-08-30 | Hoffmann La Roche | Compuestos de sulfonimidamida como moduladores de nlrp3 |
-
2022
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko unknown
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 JP JP2023572751A patent/JP2024522494A/ja active Pending
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 EP EP22731614.8A patent/EP4347571A1/en active Pending
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en active Application Filing
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240928A1 (es) | 2024-04-30 |
| EP4347571A1 (en) | 2024-04-10 |
| TW202313577A (zh) | 2023-04-01 |
| CR20230566A (es) | 2024-01-22 |
| KR20240019083A (ko) | 2024-02-14 |
| MX2023013998A (es) | 2023-12-11 |
| IL307201A (en) | 2023-11-01 |
| JP2024522494A (ja) | 2024-06-21 |
| BR112023025318A2 (pt) | 2024-02-27 |
| AR126053A1 (es) | 2023-09-06 |
| CA3216026A1 (en) | 2022-12-08 |
| CO2023016212A2 (es) | 2023-12-11 |
| US20240132471A1 (en) | 2024-04-25 |
| AU2022287224A1 (en) | 2023-09-21 |
| WO2022253936A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003491A1 (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
| SV2011003853A (es) | Compuestos organicos | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO6501196A2 (es) | Compuestos antiproliferativos, cojugados de los mismos, procedimientos para éstos y uso de los mismos | |
| NI201100108A (es) | Nuevas pirazol - 4 - n - alcoxicarboxamidas como microbicidas. | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| ECSP19041050A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| PA8855001A1 (es) | Monocarbamas | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| CO2023016204A2 (es) | Inhibidores de nlrp3 | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| CO2022000186A2 (es) | Nuevos compuestos heterocíclicos | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2023010694A2 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
| CL2023002429A1 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
| CR20150148A (es) | Azaindolinas |